Literature DB >> 29885528

Glutathione detonated and pH responsive nano-clusters of Au nanorods with a high dose of DOX for treatment of multidrug resistant cancer.

Yun Wang1, Feihu Wang1, Ying Liu2, Shaohui Xu1, Yuanyuan Shen1, Nianping Feng3, Shengrong Guo4.   

Abstract

Effects of nanosized drug delivery systems on cancer are often compromised due to their low drug loadings, premature drug release and multi-drug resistance (MDR). Herein, we reported a glutathione detonated and pH responsive nano-cluster of Au nanorods (AuNRs) with chemotherapeutic doxorubicin (DOX) and pre-chemosensitizer polycurcumin to treat MCF-7/ADR cells. The nano-cluster was prepared by self-assembling of AuNRs conjugated with DOX and amphiphilic poly(curcumin-co-dithiodipropionic acid)-b-biotinylated poly(ethylene glycol) via an emulsion/solvent evaporation technique, termed AuNR Cluster. The AuNR Cluster had a high drug loading (31.5% DOX), presenting much better aqueous solubility and stability at physiological pH than their individual AuNRs. The AuNR Cluster could be detonated to be their individual AuNRs at an intracellular concentration level of glutathione (GSH) (5 mM) and triggered to release DOX at an acidic pH (pH 6.8 or 5.0), which effectively facilitated cellular uptake of DOX (607 vs 356 a.u. for AuNRs at 12 h) and inhibited DOX efflux (471.33 vs 39.17 a.u. for free DOX at 24 h). The IC50 value of DOX against MCF-7/ADR cells for AuNR Cluster was 4.15 µg/mL, much lower than that for free DOX (90.97 µg/mL). The AuNR Cluster took much more photothermal effects than their corresponding AuNRs and presented enhanced anti-tumor effect (IC50: 2.61 µg/mL) under 808 nm laser irradiation. STATEMENT OF SIGNIFICANCE: Nano-sized drug delivery systems for anti-MDR cancer is still a challenging task. Herein, AuNR Cluster was self-assembled by individual AuNRs via emulsion/solvent evaporation technique, having a structure consisting of hydrophobic DOX/PCDA-AuNR core and hydrophilic biotin-PEG chain shell. AuNR Cluster is detonated to disintegrate and yield its individual AuNRs at an intracellular concentration level of glutathione (5 mM) and triggered to release DOX at an acidic pH (6.8 or 5.0). In comparison with its individual AuNRs, AuNR Cluster has better water solubility and stability, greater photothermal effects under NIR irradiation, bigger cytotoxicity against MCF-7/ADR cells. AuNR Cluster is expected to be a potential nanomedicine for treatment of MDR cancer.
Copyright © 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Au nanorods; Doxorubicin; Glutathione responsive disintegration; MCF-7/ADR cells; Nano-clusters

Mesh:

Substances:

Year:  2018        PMID: 29885528     DOI: 10.1016/j.actbio.2018.06.012

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  10 in total

1.  pH-Responsive Hyaluronic Acid Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy.

Authors:  Xiangle Zeng; Hairong Wang; Yawen Zhang; Xue Xu; Xinyi Yuan; Jianchun Li
Journal:  Int J Nanomedicine       Date:  2022-03-25

Review 2.  Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Authors:  Sruthi Sritharan; Sampurna Guha; Snoopy Hazarika; Nageswaran Sivalingam
Journal:  Apoptosis       Date:  2022-06-18       Impact factor: 5.561

Review 3.  Recent advances in anti-multidrug resistance for nano-drug delivery system.

Authors:  Changduo Wang; Fashun Li; Tianao Zhang; Min Yu; Yong Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  High Performance Gold Nanorods@DNA Self-Assembled Drug-Loading System for Cancer Thermo-Chemotherapy in the Second Near-Infrared Optical Window.

Authors:  Wei Chang; Junfeng Wang; Jing Zhang; Qing Ling; Yumei Li; Jie Wang
Journal:  Pharmaceutics       Date:  2022-05-23       Impact factor: 6.525

5.  Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy.

Authors:  Zhi-Peng Li; Gui-Xiang Tian; Hong Jiang; Rui-Yan Pan; Bo Lian; Min Wang; Zhi-Qin Gao; Bo Zhang; Jing-Liang Wu
Journal:  Int J Nanomedicine       Date:  2019-12-02

Review 6.  Smart Responsive Nanoformulation for Targeted Delivery of Active Compounds From Traditional Chinese Medicine.

Authors:  Xuejun Jiang; Mei Lin; Jianwen Huang; Mulan Mo; Houhe Liu; Yuan Jiang; Xiaowen Cai; Wingnang Leung; Chuanshan Xu
Journal:  Front Chem       Date:  2020-12-10       Impact factor: 5.221

Review 7.  Improvement of Gold Nanorods in Photothermal Therapy: Recent Progress and Perspective.

Authors:  Shengnan Liao; Wang Yue; Shuning Cai; Quan Tang; Weitong Lu; Lingxiao Huang; Tingting Qi; Jinfeng Liao
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 8.  Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer.

Authors:  Chengyuan Zhang; Xuemei Zhou; Hanyi Zhang; Xuanliang Han; Baijun Li; Ran Yang; Xing Zhou
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

Review 9.  Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.

Authors:  Priya Yadav; Suresh V Ambudkar; N Rajendra Prasad
Journal:  J Nanobiotechnology       Date:  2022-09-24       Impact factor: 9.429

Review 10.  Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy.

Authors:  Lei Cao; Yuqin Zhu; Weiju Wang; Gaoxiong Wang; Shuaishuai Zhang; Hongwei Cheng
Journal:  Front Bioeng Biotechnol       Date:  2021-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.